Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Lilly Ostrovsky
Medical Writer
Authored Items
Eylea (Aflibercept), a VEGF Receptor Inhibitor, Receives New Indication for All Stages of Diabetic Retinopathy
Lilly Ostrovsky
2019 Payers' Guide Mid-Year Addendum
in
Select Drug Profiles
Imbruvica (Ibrutinib) plus Gazyva (Obinutuzumab) First Chemotherapy-Free Combination Approved as First-Line Treatment for Patients with CLL or SLL
Lilly Ostrovsky
2019 Payers' Guide Mid-Year Addendum
in
Select Drug Profiles
Mavenclad (Cladribine) First Short-Course Oral Therapy Approved for Relapsing-Remitting Multiple Sclerosis and Active Secondary Progressive Disease
Lilly Ostrovsky
2019 Payers' Guide Mid-Year Addendum
in
Select Drug Profiles
Payers’ Perspective: Incorporating Real-World Evidence in Patient Care
Lilly Ostrovsky
April 2017 Vol 10, No 2
in
Conference Correspondent
,
Conference Highlights AMCP
Implications of Real-World Data and Pharmacoeconomics for Managed Care
Lilly Ostrovsky
May 2016 Vol 9, No 3
in
Conference Highlights AMCP
New Data Show Osimertinib Effective as First-Line Treatment of NSCLC with EGFR Mutation
Lilly Ostrovsky
Web Exclusives
in
In the News
,
Lung Cancer
Atezolizumab First PD-L1 Inhibitor Approved by the FDA for Advanced or Metastatic Urothelial Cancer
Lilly Ostrovsky
Web Exclusives
in
FDA Approvals
,
Select Drug Profiles
Last modified: August 13, 2019